Abenacianine + NIR Imaging for Lung Cancer

(VISUALIZE-2 Trial)

This trial tests a new method to help doctors see lung cancer during surgery. The treatment uses abenacianine, a drug that illuminates cancer cells under near-infrared (NIR) imaging, making it easier for surgeons to identify and remove cancer. Some participants will undergo surgery with this imaging, while others will have surgery without it. The trial seeks individuals scheduled for lung surgery to diagnose or treat cancer. Those planning lung surgery who have not recently received cancer treatments like chemotherapy or radiation may be suitable candidates. As a Phase 3 trial, this treatment represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking advancement in cancer surgery.

The trial information does not specify if you need to stop taking your current medications. However, if you have received chemotherapy, immunotherapy, or radiotherapy within 4 weeks before joining, you cannot participate.

Research has shown that abenacianine, a special imaging agent for detecting tumors, is safe for humans. Earlier studies found that patients undergoing lung cancer surgery generally tolerated abenacianine well. The FDA granted it fast track status due to its apparent safety and effectiveness in spotting cancer. Importantly, studies did not identify any serious side effects from its use. This suggests that abenacianine is usually safe for lung cancer surgeries, making it a good option for patients considering participation in clinical trials.¹²³⁴⁵

Abenacianine is unique because it combines with near-infrared (NIR) imaging to enhance surgical precision in lung cancer treatment. While standard treatments like chemotherapy and radiotherapy target cancer cells systemically, abenacianine is used alongside surgery to improve tumor visibility, potentially leading to more accurate removal of cancerous tissue. Researchers are excited about this approach because it may reduce the likelihood of cancer recurrence by ensuring more complete tumor excision, possibly improving outcomes and recovery times for patients.

Research has shown that abenacianine, when combined with near-infrared (NIR) imaging, can significantly enhance the visibility of lung tumors during surgery. In this trial, participants will be randomized to receive abenacianine with surgery using either standard of care (SOC) only or SOC plus NIR imaging. Earlier studies found that NIR imaging helps surgeons better identify cancerous tissues, leading to improved surgical outcomes. The FDA granted abenacianine fast track status because it effectively highlights lung tumors and is considered safe. Earlier trials found no serious side effects, supporting its potential to aid in lung cancer surgeries.¹²³⁴⁵